Myasthenia Gravis: A Systematic Review

AbstractAn autoimmune neurological condition called myasthenia gravis (MG) is typified by impaired neuromuscular junction communication. Between 4.1 and 30 cases per million person-years are the disease’s incidence. And between 150 and 200 cases per million is the prevalence rate. MG is Regarded as a quintessential illustration of antibody-mediated autoimmune Illness. The majority of MG patients develop autoantibodies against the Receptors for acetylcholine (AChRs). Less frequently recognized Among the autoantibodies directed against muscle-specific kinase (MuSK), Agrin, as well as low-density lipoprotein receptor-related protein 4 (Lrp4). Cholinergic communication between nerve cells is disrupted by these autoantibodies. Muscle fibres and terminals resulting in downregulation, damage, AChRs can be functionally blocked, or their clustering in the Membrane between synapses. The primary clinical sign of MG is Weakness in fatigable muscles that can impact the eyes, brain. KeywordsAcetylcholine, Autoantibody, B cell, Cytokinase, Neuromuscular junction.